换一批
换一批Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry.
第一作者：
Paula M,Ladwig
第一单位：
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
作者：
关键词
AMR, analytical measuring rangeC5, complement component 5DTT, dithiothreitolDa, daltonsECUL, eculizumabEculizumabFc, crystallizable fragmentHPLC, high performance liquid chromatographyIRB, Institutional Review BoardIS, internal standardIntact light chainLC, liquid chromatographyLDT, lab-developed testLLOD, lower limit of detectionLLOQ, lower limit of quantitationLOB, limit of blankMS, mass spectrometryMW, molecular weightMass spectrometryNHS, normal human serumNIVOL, nivolumabOrbitrapPBS, phosphate buffered salinePNH, paroxysmal nocturnal hemoglobinuriaQ-TOF, quadrupole time-of-flightRAVUL, ravulizumabRavulizumabTherapeutic monoclonal antibodyTime of flightXIC, extracted ion chromatogramaHUS, atypical hemolytic uremic syndromet-mAb, therapeutic monoclonal antibody
DOI
10.1016/j.jmsacl.2021.08.002
PMID
34820672
发布时间
2022-04-28
- 浏览0
Journal of mass spectrometry and advances in the clinical lab
2021年21卷
10-18页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
